2,233
Participants
Start Date
August 31, 2002
Primary Completion Date
April 30, 2010
Study Completion Date
May 31, 2010
No intervention
This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
Hoover
Mobile
Phoenix
Tucson
Madera
Oakland
Orange
Paramount
San Luis Obispo
West Covina
Centennial
Denver
Chiefland
Hollywood
Jacksonville
Blue Ridge
Marietta
‘Aiea
Boise
Nampa
Chicago
Indianapolis
Bardstown
Louisville
Metairie
New Orleans
Shreveport
Slidell
Detroit
Royal Oak
Stevensville
Omaha
Johnson City
Mineola
New York
Rochester
Akron
Cincinnati
Cleveland
Philadelphia
Pittsburgh
Charleston
Corpus Christi
Houston
Seguin
Burke
Vienna
Buenos Aires
Loma Hermosa
San Isidro
Curitiba
Porto Alegre
São Paulo
Santiago
Costa Rica
San José
Beersheba
Guadalajara
Puebla City
Toluca
Zapopan
Zona
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY